Publication:
Novel index combining Pan-Immune-Inflammatory index and hemoglobin levels (PIV/HB) predicts trismus rates efficiently after chemoradiotherapy in locally advanced nasopharyngeal cancer

dc.contributor.coauthorSomay, Efsun
dc.contributor.coauthorYilmaz, Busra
dc.contributor.coauthorTopkan, Erkan
dc.contributor.coauthorOzdemir, Beyza Sirin
dc.contributor.coauthorOzturk, Duriye
dc.contributor.coauthorBesen, Ali Ayberk
dc.contributor.coauthorMertsoylu, Huseyin
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorSelek, Uğur
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2025-03-06T20:58:45Z
dc.date.issued2024
dc.description.abstractPurpose. To evaluate the predictive potency of a novel index combining the pan-immune-inflammatory index and hemoglobin levels (PIV/Hb) for the prevalence of radiation-induced trismus (RIT) in patients with locally advanced nasopharyngeal cancer (LA-NPC) receiving concurrent chemoradiotherapy (CCRT). Methods. Data from 228 LA-NPC patients were retrospectively examined. Maximum mouth openings (MMO) were measured to confirm the presence of RIT, defined as MMOs <= 35 mm. Complete blood test results from the first day of CCRT were used to calculate PIV/Hb levels. A potential relationship between pretreatment PIV/Hb and the RIT status was evaluated using receiver operating characteristic (ROC) curve analysis. Results. Post-CCRT RIT was diagnosed in 20.2% of the patients. The ROC curve analysis determined 68.4 g/dL as the ideal PIV/Hb cutoff that effectively divided patients into two distinct groups (area under the curve: 94.7%;specificity: 86.4%;sensitivity: 87.4%). RIT was significantly more prevalent in the PIV/Hb > 68 group than in the PIV/Hb < 68 group (58.8% vs. 3.8%;P<0.001). Multivariate logistic regression analysis showed that a pre-CCRT PIV > 68 was independently associated with significantly higher rates of RIT. Conclusion. Higher pretreatment levels of the novel PIV/Hb index predict increased RIT rates following definitive CCRT for LA-NPCs.
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.identifier.doi10.1155/2024/2124006
dc.identifier.eissn2090-1410
dc.identifier.issn2090-1402
dc.identifier.quartileQ4
dc.identifier.scopus2-s2.0-85205781100
dc.identifier.urihttps://doi.org/10.1155/2024/2124006
dc.identifier.urihttps://hdl.handle.net/20.500.14288/27551
dc.identifier.volume2024
dc.identifier.wos1336561400001
dc.keywordsPIV/Hb index
dc.keywordsRadiation-induced trismus
dc.keywordsNasopharyngeal cancer
dc.keywordsChemoradiotherapy
dc.keywordsPretreatment levels
dc.keywordsPredictive index
dc.keywordsReceiver operating characteristic analysis
dc.keywordsMultivariate logistic regression
dc.keywordsMaximum mouth opening
dc.keywordsTrismus prevalence
dc.language.isoeng
dc.publisherWiley
dc.relation.ispartofINTERNATIONAL JOURNAL OF SURGICAL ONCOLOGY
dc.subjectOncology
dc.titleNovel index combining Pan-Immune-Inflammatory index and hemoglobin levels (PIV/HB) predicts trismus rates efficiently after chemoradiotherapy in locally advanced nasopharyngeal cancer
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorSelek, Uğur
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files